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Abstract
Background: Gastrointestinal stromal tumors (GIST) represent the most common mesenchymal
tumors of the digestive tract. Over the last ten years the management of GISTs has dramatically
altered but their coexistence with other gasrointesinal tumors of different histogenesis presents a
special interest. The coexistence of GISTs with other primaries is usually discovered incidentally
during GI surgery for carcinomas.
Case presentation: We present here, a case of a 66-year-old patient with intestinal GIST and a
synchronous colorectal adenocarcinoma discovered incidentally during surgical treatment of the
recurrent GIST. Immunohistochemical examination revealed the concurrence of histologically
proved GIST (strongly positive staining for c-kit, vimentin, SMA, and focal positive in S-100, while
CD-34 was negative) and Dukes Stage C, (T3, N3, M0 according the TNM staging classification of
colorectal cancer).
Conclusion: The coexistence of GIST with either synchronous or metachronous colorectal
cancer represents a phenomenon with increasing number of relative reports in the literature the
last 5 years. In any case of GIST the surgeon should be alert to recognize a possible coexistent
tumor with different histological origin and to perform a thorough preoperative and intraoperative
control. The correct diagnosis before and at the time of the surgical procedure is the cornerstone
that secures the patients' best prognosis.
Background
Gastrointestinal stromal tumors (GISTs) are specific mes-
enchymal tumors that may occur anywhere along the gas-
trointestinal tract [1,2]. It is currently defined as
gastrointestinal tract mesenchymal tumor containing
spindle cells (less commonly epithelioid cells or both)
and showing CD-117 (c-kit protein) and vimentin posi-
tivity [1,3,4]
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GISTs are rare neoplasms and represent the 0.1–3% of all
gastrointestinal cancers and the most common mesenchy-
mal tumor of the digestive tract (20% of small bowel
malignancies & approximately 5% of all tissue sarcomas)
[5,6].
Over the last years the management of GISTs has evolved
rapidly. A lot of changes have been reported in histologi-
cal diagnostic criteria, in understanding of GISTs' molecu-
lar biology and pathogenesis, in imaging strategy, in
surgical and adjuvant treatment etc [7]. Although the out-
comes of several published series helped in understanding
their pathogenesis, little is known about their coincidence
with other tumors of different histogenesis. There are
some data regarding the co-occurrence, the association
and the potential common origin (genetic pathways of
tumorigenesis), between GIST and other tumors [7,8].
The limited number of these cases can not confirm the
existence of a common factor in tumorigenesis of these
histopathologically completely different tumors and fur-
ther studies are needed to clarify the possible association
[9].
The coexistence of GISTs with other primaries is usually
discovered incidentally during GI surgery for carcinomas
[10-12]. Here in, we describe the reverse of the common
situation, as a cecal adenocarcinoma was incidentally dis-
covered during surgery for recurrent intestinal GIST.
Case presentation
A 66-year-old man was admitted to our clinic two years
ago complaining abdominal discomfort associated with
distension, pain, and symptoms related to small intestine
bowel obstruction (vomiting and obstipation). On physi-
cal examination a palpable mass in the lower right abdo-
men was found. CT scan of the abdomen and pelvis
demonstrated a large (9 × 6.5 × 7 cm) low-density, well
circumscribed mass in the right lower abdomen, without
evidence of tumor infiltration of adjacent structures and
without free fluid. No metastatic nodules were found in
the liver and the lung.
Laparotomy revealed a pedunculated, ulcerative and fria-
ble large mass (a small bowel mass greater than 10 cm)
with the features of gastroimtestinal stromal tumor: the
surrounding organs (sigmoid colon, rectum, ureters and
bladder) were pushed but not involved by the tumor. Fur-
thermore, remarkable intraabdominal metastatic spread
consisted of multiple small nodular lesions – less than 2
cm in size – all over the peritoneal surface and between
bowel loops, was encountered. No evidence of liver
metastasis or lymphadenopathy was found. The patient
underwent an en-block resection of the tumor along with
all visible disease in order to avoid capsule rupture and
intraabdominal spillage, as is recommended [7]. A small
bowel resection with an end to end primary anastomosis
was performed. Numerous peritoneal nodal metastases
were excised and sent for histological analysis.
Histopathological examination of the resected specimens
revealed a stromal cell neoplasm with necrotic and hem-
orrhagic areas and a high index of mitotic count: 8–10
mitoses per high-power fields (HPF). Immunohistochem-
ical analysis revealed C-kit (strongly positive),
SMA(strongly positive), focal S-100(+) and CD34(-). The
result of histological examination confirmed also the
existence of intraabdominal metastatic spread.
Following the histopathological confirmation, immediate
treatment with imatinib was initiated. The imatinib was
introduced in dose of 400 mg/day without interruption
(in order to minimize the risk of relapse associated with
the drug interruption) [10]. Postoperatively, patient was
followed up with CT scan. According to the clinical, surgi-
cal and histopathological features, our patient was
included in the high risk group for recurrence. The patient
underwent a CT scan of the abdomen and the pelvis in
regular 4–6 months intervals [13,14].
The CT scan performed 2 years after surgical excision and
treatment commencement, revealed metastatic liver dis-
ease. Dose escalation (400 mg of imatinib mesylate twice
a day) was decided and initiated. Six months later, liver
lesion was presented with a characteristic size increase
(figure 1a). Furthermore, a small soft tissue mass (3,3 ×
2,8 × 3 cm) in the right lower abdomen was revealed in
the abdominal CT scan. The mass was localized at the ana-
tomic area of the previous excision and was considered
either as another metastatic lesion or as a possible local
recurrence (figure 1b).
Laparotomy confirmed the presence of liver metastasis,
localized between the Segment V & Segment VI as well as
intra-abdominal metastatic spread (multiple small nodu-
lar lesions – less than 1 cm in size – all over the peritoneal
surface and between bowel loops). An intestinal mass was
also found 60 cm proximal to the ileocecal valve. Surpris-
ingly, during the thorough exploration of the peritoneal
cavity, another mass with completely different macro-
scopic features was discovered. It was a palpable cecal
mass, without extracanalicular growth or infiltration into
other organs, associated with local lymph-node enlarge-
ment.
Intra-abdominal ultrasound (IOUS) was performed in
order to assist in liver resection planning (mainly to ena-
ble detection of additional tumors, missed in preoperative
CT scan imaging and to evaluate the relationship between
metastatic lesions and major vascular structures).World Journal of Surgical Oncology 2007, 5:96 http://www.wjso.com/content/5/1/96
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RFA (Radio Frequency Ablation)-assisted liver resection
[15] of segments V, VI was performed and a segmental
small-bowel resection along with excision of all gross vis-
ible peritoneal nodular lesions followed. Finally, a right
hemicolectomy was decided in order to treat the "unex-
pected" cecal lesion.
At this point is important to underline that surgery
remains the mainstay therapy for both (GIST and colorec-
tal cancer) although the operative strategies and extent of
resection are fairly different. [12] Given the rarity of
lymph-node involvement, routine lymphadenectomy is
not currently recommended in GIST cases. [13,16] At the
present case because of local lymph-node enlargement a
curative resection was performed (included the resection
of the lymphatic station), aiming to obtain microscopic
disease-free radial and distal margins.
Gross examination of the 29 cm specimen disclosed a 7 ×
4 cm tumor originating from the cecum and two polyps
located about 7 cm from the cecum. The liver specimen
(8.5 × 6.5 × 3.7 cm, segments V, VI) weighted 90 gr and
contained the 5 cm metastatic lesion.
Histopathological examination of the resected specimen
(figure 2) revealed a recurrent intestinal GIST (figure
2A,B) with malignant biological behavior and a moder-
ately differentiated stage Dukes C (T3, N3, M0 according
the TNM staging classification of colorectal cancer) cecal
adenocarcinoma (figure 2C).
The specimen had the following characteristics: a) meta-
static liver tumor with mesenhymal origin characterized
by necrotic and bleeding areas (figure 2D) and a mitotic
count of <5/50 HPF. Immunohistochemical staining
revealed a strongly (+) reaction for c-kit, slight (+) for S-
100, and no specific staining for CD34 and desmin. The
surgical margins of the resected hepatic specimen were
free from invasion, b) moderately differentiated adeno-
carcinoma with a slight extracellular, mucus production.
The tumor invaded the muscularis propria and the perico-
lonic adipose tissue. The neoplastic tissue extended and
infiltrated the small bowel wall but the proximal and dis-
tant surgical margins were free.
Four of the examined lymph nodes presented metastatic
invasion from GIST and 12 from colorectal adenocarci-
noma. The above mentioned morphologic and immuno-
chistochemical findings are diagnostic for coexistence of
GIST and colorectal adenocarcinoma
Discussion
Gastrointestinal stromal tumors are uncommon and their
pathogenesis, diagnosis, nomenclature, and prognosis
have long been a subject of considerable controversy. The
stromal tumors designated as GISTs are identified by a
series of histological, molecular, genetic and in particular,
immunophenotypic features that set them apart from
common leiomyomas, leiomyosarcomas of the GI-tract.
Recent studies suggest that GISTs represent a subgroup of
gastrointestinal mesenchymal tumors arising from a com-
mon precursor cell, the interstitial cell of Cajal, or a prim-
itive stem cell from which both Cajal cells and smooth
muscle cells arise [3]. Gastrointestinal stromal tumors are
currently defined as c-kit (CD117)-positive spindle cell
(or, less commonly, epithelioid cell or both) gastrointes-
tinal tract mesenchymal tumors [1,3].
The most important markers for defining GISTs are
CD117 (c-kit protein) and CD 34 (hematopoietic cell pro-
genitor antigen). The majority of GISTs are usually posi-
tive for CD117 (near 95% of cases), CD34 (positive in
70–80% of cases), smooth muscle actin (positive in 40%
of cases), PS 100 (positive near 5% of cases), and desmin
(positive in approximately 2% of cases) [1-3].
Although the demonstration of c-kit (CD117) immunore-
activity represents the gold standard for diagnosis of GIST
(it's also considered as an eligibility criterion for Imatinib
Masylate therapy) [2,3] approximately 5% of histologo-
cally suspected GIST are CD117 negative [1,17,18].
Gastrointestinal stromal tumors may occur anywhere
along the digestive tract. They may be found anywhere
between the esophagus and the anus. Additional locations
have been found to include omentum, mesentery and ret-
roperitoneum [18,19,21]. Most GISTs arise from the
stomach (50–62%), from the small intestine (20–30%),
the colon (11%), the rectum (7%) while the esophagus is
rarely involved (0,6–1%) [19,20,22].
It is well known that GISTs have the potential to metasta-
size (at first diagnosis many patients present with meta-
static spread (11–47%) [22] either via blood stream or via
peritoneal seeding and they give rise to liver or omental
A: CT scan of the abdomen revealing, A: a 5 × 5.2 cm liver  mass (white arrow) located between segments V and VI and  B: a 4 × 3.8 cm soft tissue mass (white arrow) in the right  abdomen between bowel loops Figure 1
A: CT scan of the abdomen revealing, A: a 5 × 5.2 cm liver 
mass (white arrow) located between segments V and VI and 
B: a 4 × 3.8 cm soft tissue mass (white arrow) in the right 
abdomen between bowel loops.World Journal of Surgical Oncology 2007, 5:96 http://www.wjso.com/content/5/1/96
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metastases. Lung, bones and lymph node metastases are
rare [1,2]. GISTs' malignant potential is considered to
depend on tumor size, frequency of mitoses, presence of
necrosis, and the possible invasion to adjacent organs [21-
24] but there is also a relevance to the anatomic site of ori-
gin [3].
In the described case, a 66-year-old male was operated pri-
marily for a small bowel tumor in surgical emergency set-
ting. The tumor was treated as malignant because,
according to the guidelines, in a surgical emergency or in
the absence of a preoperative diagnosis, even in the pres-
ence of a single mass without evidence of contiguous
organ involvement or metastatic disease, the surgeon is
responsible to recognize and to treat these lesions as
malignant [25]. Histopathologic findings confirmed the
presence of intestinal GIST with a highly malignant
behavior. Reported series in pre-imatinib era indicated
that the complete surgical excision, although technically
feasible, is not curative and the use of imatinib in unre-
sectable and/or metastatic disease is recommended [13].
Indeed, the patient was further treated with imatinib
mesylate and underwent the indicated by ESMO follow
up.
Two years after treatment initiation, during follow-up CT
scan, a liver mass was found. The liver mass failed to
respond to the appropriate imatinib dose escalation (400
mg twice day). Additionally, at the subsequent follow up,
an intestinal mass at the site of previous surgical excision
was discovered, which was initially confused with other
similar metastatic lesions demonstrated between small
bowel loops.
Surgery followed and the subsequent histopathological
examination confirmed the presence of the GIST liver
metastasis and a moderately differentiated cecal adeno-
carcinoma. a fact that renders the potential promising
therapeutic impact of imatinib mesylate in the prevention
of colorectal cancer controversial (this was shown by the
inhibition of the in vitro growth of the colorectal carci-
noma cell lines) [26].
There is a continuously increasing knowledge about syn-
chronous presentation of GIST and other gastrointestinal
tumors. The major types of GIST-associated malignancies
reported in literature are: gastrointestinal carcinomas
(gastric and colon cancer), lymphoma/leukemia, gyneco-
logical carcinomas, and carcinomas of prostate, breast,
pancreas, lung, liver, kidney as well as carcinoid of pan-
A: Small intestine GIST in H-E stain (×20); B: C-kit immunoexpression (×40); C: Adenocarcinoma of cecum in H-E stain (×20);  D: C-kit immunoreactivity in metastatic GIST of liver (×20) Figure 2
A: Small intestine GIST in H-E stain (×20); B: C-kit immunoexpression (×40); C: Adenocarcinoma of cecum in H-E stain (×20); 
D: C-kit immunoreactivity in metastatic GIST of liver (×20).World Journal of Surgical Oncology 2007, 5:96 http://www.wjso.com/content/5/1/96
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creas and stomach [10-12,27-30]. Although uncommon,
the fact that patients who have a history of soft tissue sar-
comas (STS) are in an increased risk for the development
of GIST, presents a special interest [30,31].
Even if the synchronous occurrence of GIST and colorectal
adenocarcinomas is not extremely rare little is yet known
their potential common origin and carcinogenetic path-
ways. The limited number of reported cases cannot rule
out a possible incidental occurrence though [32,33]. The
majority of the coexistent GISTs are discovered inciden-
tally during work-up or during therapeutic procedures for
GI malignancies. What is unique in the present case is that
synchronous cecal adenocarcinoma was incidentally dis-
covered during laparotomy for recurrent GIST disease.
What should be delineated at this point is the undeniable
possible coexistence of a synchronous tumor with a pri-
mary or recurrent GIST. This fact underlines the signifi-
cance of a detailed preoperative imaging study which
should include contrast enhanced CT scans of the abdo-
men and pelvis. Other modalities used in the evaluation
of GISTs include MRI and Fluorodeoxyglcose positron
emission tomography (PET) but CT is currently the imag-
ing modality of choice. Above all, we should emphasize
the importance of a thorough intrabdominal exploration
by an experienced surgeon in order not to overlook a pos-
sible mass that could hide a synchronous cancer.
Conclusion
The coexistence of GIST with either synchronous or meta-
chronous colorectal cancer represents a phenomenon
with increasing number of relative reports in the literature
the last 5 years.
In any case of GIST (with or without preoperative his-
topathological confirmation) the surgeon should be alert
to recognize a possible coexistent tumor with different
histological origin and to perform a thorough preopera-
tive and intraoperative control. The correct diagnosis
before and at the time of the surgical procedure is the cor-
nerstone that secures the patients' best prognosis.
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